type 2 diabetes, diabetic kidney disease
Conditions
Interventions
None listed
Sponsors
Department of Internal Medicine,Ehime Rousai Hospital, Niihama, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subject were type 2 diabetic outpatients who were newly prescribed EPA (ethyl icosapentate: 1800mg/day) for managing hypertriglyceridemia or due to the diagnosis of having cardiovascular disease (CVD) risk.
Exclusion criteria
Exclusion criteria: We excluded patients who have any one of the following criteria: [1] receiving hemodialysis; [2] being suspected of having kidney disease other than DKD; [3] being suspected of having muscle atrophy because of gait disturbance; [4] being treated with SGLT2i and GLP-1RAs; [5] received additional prescription of new class of glucose-lowering drugs, or new agents which can influence eGFR, within one year from the initiation of EPA administration; [6] new onset of systemic disease; [7] whose eGFR was measured less than six times during the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of eGFR, which was calculated by subtracting eGFR at the initiation of EPA administration (baseline) from eGFR after 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes were the changes in of BMI, BP, UACR, E-A ratio, HbA1c, UA, TG, TC, LDL-C, HDL-C, L-H ratio and non-HDL-C | — |
Countries
Japan
Contacts
Public ContactKazuaki Nakai
Ehime Rousai Hospital Department of Internal Medicine
Outcome results
None listed